Friedreich's Ataxia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations
Expert Rev Neurother. 2024 Mar;24(3):251-258. doi: 10.1080/14737175.2024.2310617. Epub 2024 Jan 30.ABSTRACTINTRODUCTION: Omavaloxolone, an NRF2 activator, recently became the first drug approved specifically for the treatment of Friedreich ataxia (FRDA). This landmark achievement provides a background for a review of the detailed data leading to the approval.AREAS COVERED: The authors review the data from the 4 major articles on FRDA in the context of the authors' considerable (>1000 patients) experience in treating individuals with FRDA. The data is presented in the context not only of its scientific meaning but also i...
Source: Expert Review of Neurotherapeutics - January 25, 2024 Category: Neurology Authors: David R Lynch Susan Perlman Kim Schadt Source Type: research